GSK again scores $235M in ‘skinny label’ case, but court admits it’s ‘unclear what Teva even did wrong’news2021-08-06T13:59:43+00:00August 6th, 2021|Fierce Pharma|
Spectrum’s Rolontis, angling to rival Amgen’s Neulasta, hit with FDA rejection over manufacturing ‘deficiencies’news2021-08-06T13:40:14+00:00August 6th, 2021|Fierce Pharma|
AstraZeneca chief Soriot lends GlaxoSmithKline’s Walmsley CEO wisdom, support as activist investors press for changenews2021-08-06T13:25:48+00:00August 6th, 2021|Fierce Pharma|
While Novo’s GLP-1 meds post big gains, the company is still looking to create an insulin ‘revolution,’ CEO saysnews2021-08-06T12:32:14+00:00August 6th, 2021|Fierce Pharma|
Gilead Foundation bounces back with a bang—$200M in the bank and ambitious goalsnews2021-08-06T11:59:18+00:00August 6th, 2021|Fierce Pharma|
Fierce Pharma Asia—BeiGene’s flagship U.S. hub, Brukinsa win; Takeda’s tax bill, regulatory delaysnews2021-08-06T10:14:33+00:00August 6th, 2021|Fierce Pharma|
Sanofi, Regeneron stop Libtayo-chemo lung cancer trial early on strong survival datanews2021-08-05T15:36:42+00:00August 5th, 2021|Fierce Pharma|
Regeneron’s COVID-19 antibodies rake in $2.6B, reflecting their market dominance and blowing away estimatesnews2021-08-05T15:18:18+00:00August 5th, 2021|Fierce Pharma|
‘The kidney medicine’: Bayer touts Kerendia’s blockbuster potential as its pharma group swings back to growthnews2021-08-05T14:22:35+00:00August 5th, 2021|Fierce Pharma|
Moderna, citing variants and waning immunity, expects COVID-19 boosters to become a fact of lifenews2021-08-05T14:03:35+00:00August 5th, 2021|Fierce Pharma|
